6-氰基-3-吡啶羰酰氯 | 313350-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氰基-3-吡啶羰酰氯
• 中文别名: 6-氰基烟酰基氯化物
• 英文名称: 6-cyano-nicotinoyl chloride
• 英文别名: 6-cyanopyridine-3-carbonyl chloride
• CAS: 313350-44-6
• 化学式: C₇H₃ClN₂O
• 分子量: 166.567
• InChiKey: KSVWNAJTQHVDTP-UHFFFAOYSA-N

物化性质

• 沸点：
  332.4±27.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-氰基-3-吡啶羰酰氯 在 sodium azide 、 三乙胺 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 2.17h， 生成 5-异氰酸吡啶-2-甲腈
  参考文献：
  名称：

  (+)-(2R,5S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an Orally Potent and Peripherally Selective Nonsteroidal Androgen Receptor Antagonist

  摘要：

  A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

  DOI：

  10.1021/jm050293c
• 作为产物：
  描述：

  氧烟酸 在 三甲基氯硅烷 、 氯化亚砜 作用下， 生成 6-氰基-3-吡啶羰酰氯
  参考文献：
  名称：

  Novel coordinating motifs for lanthanide(iii) ions based on 5-(2-pyridyl)tetrazole and 5-(2-pyridyl-1-oxide)tetrazole. Potential new contrast agents

  摘要：

  水溶性和中性Ln(III)及Zn(II)吡啶和（吡啶-1-氧化物）四唑配合物已被合成，其中Gd衍生物具有成为高弛豫性低渗透压MRI造影剂的巨大潜力。

  DOI：

  10.1039/b401919a

文献信息

• Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria
  作者：Sreekanth Kokkonda、Xiaoyi Deng、Karen L. White、Farah El Mazouni、John White、David M. Shackleford、Kasiram Katneni、Francis C. K. Chiu、Helena Barker、Jenna McLaren、Elly Crighton、Gong Chen、Inigo Angulo-Barturen、Maria Belen Jimenez-Diaz、Santiago Ferrer、Leticia Huertas-Valentin、Maria Santos Martinez-Martinez、Maria Jose Lafuente-Monasterio、Rajesh Chittimalla、Shatrughan P. Shahi、Sergio Wittlin、David Waterson、Jeremy N. Burrows、Dave Matthews、Diana Tomchick、Pradipsinh K. Rathod、Michael J. Palmer、Susan A. Charman、Margaret A. Phillips

  DOI：10.1021/acs.jmedchem.0c00311

  日期：2020.5.14

  Compounds with nanomolar potency versus Plasmodium DHODH and Plasmodium parasites were identified with good pharmacological properties. X-ray studies showed that the pyrroles bind an alternative enzyme conformation from 1 leading to improved species selectivity versus mammalian enzymes and equivalent activity on Plasmodium falciparum and Plasmodium vivax DHODH. The best lead DSM502 (37) showed in vivo efficacy

  疟疾使世界上近一半的人口面临风险，并导致撒哈拉以南非洲地区的高死亡率，而耐药性也威胁着现有的治疗方法。根据我们的发现，三唑并嘧啶 DSM265 (1) 在临床研究中显示出疗效，嘧啶生物合成酶二氢乳清酸脱氢酶 (DHODH) 是疟疾治疗的有效靶点。在此，我们描述了使用基于目标的 DHODH 筛选鉴定的基于吡咯的系列的优化。与疟原虫 DHODH 和疟原虫寄生虫相比具有纳摩尔效力的化合物已被鉴定具有良好的药理学特性。X 射线研究表明，吡咯与 1 的替代酶构象结合，从而提高了相对于哺乳动物酶的物种选择性，并且对恶性疟原虫和间日疟原虫 DHODH 具有同等活性。最好的先导 DSM502 (37) 在与 1 的血液暴露水平相似的情况下显示出体内功效，尽管代谢稳定性有所降低。总体而言，基于吡咯的 DHODH 抑制剂为新型抗疟化合物的开发提供了一种有吸引力的替代支架。
• Amide substituted imidazoquinolines
  申请人：3M Innovative Properties Company

  公开号：US06756382B2

  公开（公告）日：2004-06-29

  Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

  Imidazoquinoline和在1-位置含有酰胺功能团的四氢咪唑喹啉化合物可用作免疫应答调节剂。本发明的化合物和组合物可以诱导各种细胞因子的生物合成，并可用于治疗包括病毒性疾病和肿瘤性疾病在内的各种疾病。
• [EN] INDAZOLES<br/>[FR] INDAZOLES
  申请人：PFIZER LTD

  公开号：WO2013014567A1

  公开（公告）日：2013-01-31

  The present invention relates to compounds of formula (I) to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

  本发明涉及式(I)化合物及其药学上可接受的盐和该化合物及盐的药学上可接受的溶剂，其中取代基在此定义；含有这种化合物的组合物；以及这种化合物在治疗各种疾病，特别是哮喘和慢性阻塞性肺疾病中的用途。
• Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
  申请人：——

  公开号：US20040192720A1

  公开（公告）日：2004-09-30

  This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

  这项发明涉及新颖的烷基酰胺衍生物，作为布雷金肽受体拮抗剂，用于治疗布雷金肽调节的疾病，如疼痛、炎症、哮喘和过敏。此外，该发明涉及新颖的烷基酰胺衍生物，作为布雷金肽受体激动剂，用于治疗布雷金肽调节的疾病，如高血压等。
• AMIDE SUBSTITUTED IMIDAZOQUINOLINES
  申请人：Coleman Patrick L.

  公开号：US20090023722A1

  公开（公告）日：2009-01-22

  Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

  在1位点含有酰胺官能团的咪唑喹啉和四氢咪唑喹啉化合物可用作免疫应答调节剂。本发明的化合物和组合物可以诱导各种细胞因子的生物合成，并可用于治疗包括病毒性疾病和肿瘤性疾病在内的多种疾病。